Immunoglobulin Patents (Class 536/23.53)
-
Publication number: 20150098945Abstract: The present invention relates to an antibody having an anti-angiogenesis activity. More specifically, the present invention relates to an antibody against ROBO4 and a pharmaceutical composition containing the antibody. An object of the present invention is to provide an anti-ROBO4 antibody having an anti-angiogenesis effect, a pharmaceutical composition or the like comprising the antibody, a method for suppressing angiogenesis using the antibody, etc. Another object of the present invention is to provide a method for producing the antibody. The antibody of the present invention activates the downstream signal of ROBO4 and has a suppressive activity against cell migration induced by VEGF or bFGF. The antibody of the present invention also exhibits an anti-angiogenic effects in in-vivo models.Type: ApplicationFiled: April 26, 2013Publication date: April 9, 2015Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Yoshitaka Isumi, Toshiyuki Sato, Jun Hasegawa, Tatsuya Inoue
-
Publication number: 20150099298Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: May 8, 2013Publication date: April 9, 2015Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
-
Publication number: 20150099302Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.Type: ApplicationFiled: December 16, 2014Publication date: April 9, 2015Inventors: Ugur Sahin, Ozlem Tureci, Torsten Seppmann, Holger Hoff, Jens Schumacher
-
Publication number: 20150098900Abstract: The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: June 24, 2014Publication date: April 9, 2015Inventors: Allen J. Ebens, Meredith C. Hazen, Jo-Anne Hongo, Jennifer W. Johnston, Teemu T. Junttila, Ji Li, Andrew G. Polson
-
Publication number: 20150098939Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.Type: ApplicationFiled: August 29, 2014Publication date: April 9, 2015Applicant: SANOFIInventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
-
Publication number: 20150098946Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: April 9, 2015Applicant: Genentech, Inc.Inventors: Sunil Bhakta, Meredith Hazen, Jo-Anne S Hongo, Jagath R Junutula, Isidro Hotzel, Yonglei Shang, Shang-Fan Yu
-
Publication number: 20150099278Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: December 19, 2014Publication date: April 9, 2015Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
-
Publication number: 20150098947Abstract: Provided herein are monoclonal antibodies against Olfml-3. In some aspects, methods for treating angiogenesis-related conditions, such as cancer, are provided comprising administering an Olfml-3-binding antibody of the embodiments.Type: ApplicationFiled: October 9, 2014Publication date: April 9, 2015Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
-
Publication number: 20150099861Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.Type: ApplicationFiled: September 12, 2012Publication date: April 9, 2015Applicant: GENZYME CORPORATIONInventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
-
Publication number: 20150098949Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: September 3, 2014Publication date: April 9, 2015Inventors: AUSTIN L. GURNEY, AARON KEN SATO, CHRISTOPHER JOHN BOND
-
Patent number: 8999708Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: October 3, 2013Date of Patent: April 7, 2015Assignee: Novartis AGInventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
-
Publication number: 20150093386Abstract: Multi-functional antibody polypeptide comprises: (a) a first functional domain, specifically recognizing a cryptic epitope formed by 287th to 302nd amino acid sequence of the EGFR, shown as SEQ ID NO:1, and (b) a second functional domain, specifically recognizing the surface antigen of a human T cell.Type: ApplicationFiled: March 4, 2013Publication date: April 2, 2015Inventors: Zonghai Li, Hua Jiang, Bizhi Shi, Huamao Wang, Juan Kong, Huiping Gao
-
Publication number: 20150093392Abstract: The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for detecting CDH17, as well as methods for treating carious cancers, including gastric cancer, pancreatic cancer, colon cancer and colorectal cancer, are disclosed.Type: ApplicationFiled: November 20, 2014Publication date: April 2, 2015Inventors: Jonathan Alexander TERRETT, Christian ROHLFF
-
Publication number: 20150093336Abstract: The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.Type: ApplicationFiled: March 15, 2013Publication date: April 2, 2015Inventors: Jo Van Ginderachter, Patrick De Baetselier, Nick Devoogdt, Tony Lahoutte, Damya Laoui, Kiavash Movahedi, Geert Raes, Steve Schoonooghe
-
Publication number: 20150093384Abstract: The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism.Type: ApplicationFiled: September 12, 2014Publication date: April 2, 2015Inventors: Charles B. Shoemaker, Jorge A. Sepulveda Toepfer, Jean Mukherjee
-
Publication number: 20150093395Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20150093387Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: August 22, 2014Publication date: April 2, 2015Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
-
Patent number: 8992913Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.Type: GrantFiled: June 12, 2013Date of Patent: March 31, 2015Assignee: Pfizer Inc.Inventors: Michelle M. Mader, James R. Apgar, Kevin D. Parris
-
Patent number: 8993261Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.Type: GrantFiled: March 15, 2013Date of Patent: March 31, 2015Assignee: Merck Patent GmbHInventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
-
Patent number: 8993731Abstract: A humanized agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO: 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4+JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.Type: GrantFiled: March 9, 2011Date of Patent: March 31, 2015Assignee: UCB Biopharma SPRLInventor: Kerry Louise Tyson
-
Patent number: 8993265Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.Type: GrantFiled: May 12, 2014Date of Patent: March 31, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
-
Publication number: 20150086539Abstract: The subject relates to a cross-neutralizing antibody comprising at least one polyspecific binding site that binds to alpha-toxin (Hla) and at least one of the bi-component toxins of Staphylococcus aureus, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated conformational epitope recognized by a specific cross-neutralizing antibody.Type: ApplicationFiled: April 17, 2013Publication date: March 26, 2015Inventors: Eszter Nagy, Adriana Badarau, Harald Rouha, Lukas Stulik, Gábor Nagy, Irina Mirkina, Zoltán Magyarics, Zehra Visram, Michaela Jaegerhofer, Manuel Zerbs, Ivana Dolezilkova, Astrid Teubenbacher, Michael Benjamin Battles, Bianka Dominique Prinz
-
Publication number: 20150087819Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.Type: ApplicationFiled: December 5, 2014Publication date: March 26, 2015Inventors: SIMON MARK JACKSON, NIGEL PELHAM CLINTON WALKER, DEREK EVAN PIPER, BEI SHAN, WENYAN SHEN, JOYCE CHI YEE CHAN, CHADWICK TERENCE KING, RANDAL ROBERT KETCHEM, CHRISTOPHER MEHLIN, TERESA ARAZAS CARABEO, QIONG CAO
-
Publication number: 20150086561Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: ApplicationFiled: September 25, 2014Publication date: March 26, 2015Inventors: Lawrence M. KAUVAR, Stefan RYSER, Angeles ESTELLES, Robert STEPHENSON, Reyna J. SIMON, Omar NOURZAIE
-
Publication number: 20150086558Abstract: Antibodies binding to junction regions between the CH4 and C?mX domains of membrane-bound IgE and uses thereof in treating IgE-mediated diseases such as allergic diseases.Type: ApplicationFiled: March 14, 2013Publication date: March 26, 2015Applicant: Academia SinicaInventors: Tse Wen Chang, Jiun-Bo Chen, Chien-Jen Lin, Nien-Yi Chen
-
Publication number: 20150086546Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: December 3, 2014Publication date: March 26, 2015Inventors: Gregory J. Larosa, Christopher J. Horvath, Walter Newman, Stephan T. Jones, Siobhan H. O'Brien, Theresa L. O'Keefe
-
Publication number: 20150086568Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.Type: ApplicationFiled: November 20, 2014Publication date: March 26, 2015Applicant: GENENTECH, INC.Inventors: Germaine FUH, Chingwei V. LEE
-
Publication number: 20150086538Abstract: The present invention relates to methods for improving biophysical properties, including the stability of antibody lambda light chains, to antibody lambda light chains with improved biophysical properties, including stability, nucleic acid and vectors encoding such antibody lambda light chains, and to uses of such antibody lambda light chains, nucleic acid and vectors.Type: ApplicationFiled: April 11, 2013Publication date: March 26, 2015Inventor: Roland Beckmann
-
Publication number: 20150086978Abstract: The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.Type: ApplicationFiled: December 10, 2014Publication date: March 26, 2015Inventors: Syamal RAYCHAUDHURI, Raymond L. HOUGHTON, Stanislaw MORKOWSKI, Yvonne STEVENS, Mohua BOSE, James William NEEDHAM, Hongjing CHEN
-
Publication number: 20150086556Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.Type: ApplicationFiled: April 24, 2014Publication date: March 26, 2015Applicant: Amgen Inc.Inventors: Huiquan Han, Qing Chen, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20150086478Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.Type: ApplicationFiled: May 2, 2013Publication date: March 26, 2015Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
-
Publication number: 20150086552Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.Type: ApplicationFiled: May 21, 2013Publication date: March 26, 2015Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty, Milan Gao, Steven Sheriff, Noah Ditto, Nels B. Hamacher
-
Patent number: 8986954Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.Type: GrantFiled: May 23, 2014Date of Patent: March 24, 2015Assignee: UCB Pharma S.A.Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
-
Patent number: 8987423Abstract: Antigen binding proteins, such as antibodies, which bind to human MAGE-A3, polynucleotides encoding such antigen binding proteins, and uses and manufacture thereof.Type: GrantFiled: July 20, 2011Date of Patent: March 24, 2015Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Alain Bergeron, Normand Blais, Remi M. Palmantier, Anthony Pilorget, Yves Fradet
-
Publication number: 20150079104Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.Type: ApplicationFiled: October 8, 2014Publication date: March 19, 2015Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
-
Publication number: 20150079093Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.Type: ApplicationFiled: January 14, 2013Publication date: March 19, 2015Inventor: Gernot Stuhler
-
Publication number: 20150079070Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 10, 2014Publication date: March 19, 2015Applicant: Genzyme CorporationInventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
-
Publication number: 20150080556Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER
-
Publication number: 20150079088Abstract: The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: July 25, 2014Publication date: March 19, 2015Inventors: Henry Bernard Lowman, James William West, Sherry Lynn La Porte, Bryan Allen Irving, Daniel Robert Hostetter, Chihunt Wong
-
Patent number: 8980257Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.Type: GrantFiled: May 17, 2011Date of Patent: March 17, 2015Assignee: Medical & Biological Laboratories Co., Ltd.Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
-
Patent number: 8981072Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.Type: GrantFiled: December 10, 2013Date of Patent: March 17, 2015Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Steven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
-
Patent number: 8981071Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.Type: GrantFiled: December 22, 2010Date of Patent: March 17, 2015Assignees: Amgen, Inc., Medarex, L.L.C.Inventors: Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
-
Publication number: 20150071854Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: September 18, 2014Publication date: March 12, 2015Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Publication number: 20150071926Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.Type: ApplicationFiled: February 26, 2013Publication date: March 12, 2015Inventors: Andrzej Fertala, Andrzej Steplewski
-
Publication number: 20150071923Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: September 12, 2014Publication date: March 12, 2015Inventors: Ge Wei, Gregory I. Frost, H. Michael Shepard, Christopher D. Thanos
-
Publication number: 20150071927Abstract: Disclosed are antibodies, or binding fragments thereof, that specifically bind to human HER2 and human IGF-IR. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules. The disclosure also provides methods of inhibiting cancer cell growth and metastasis in a mammal using the antibodies described herein, as well as compositions containing the antibodies, nucleic acid molecules encoding the antibodies, and host cells and vectors comprising the nucleic acid molecules. The disclosure also features the use of the polypeptides to detect the presence of HER2 and IGF-IR in a mammal, and epitopes that can be used as cancer vaccine immunogens.Type: ApplicationFiled: September 11, 2014Publication date: March 12, 2015Inventor: Mei-Yun Zhang
-
Publication number: 20150071937Abstract: This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.Type: ApplicationFiled: September 15, 2014Publication date: March 12, 2015Inventors: BIN LIU, JAMES D. MARKS
-
Patent number: 8975378Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: GrantFiled: December 24, 2009Date of Patent: March 10, 2015Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Patent number: 8974785Abstract: The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.Type: GrantFiled: April 16, 2010Date of Patent: March 10, 2015Assignee: Shanghai Biomabs Pharmaceuticals Co., Ltd.Inventors: Chuan Li, Xin Tong, Ying Kan
-
Patent number: 8975391Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: GrantFiled: February 22, 2013Date of Patent: March 10, 2015Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Barbara Enenkel